CRTAC1 as A Potential Drug Target for Neurological Disorders (G55118)

Target Name: CRTAC1

NCBI ID: G55118

CRTAC1

CRTAC1 as A Potential Drug Target for Neurological Disorders

CRTAC1 (CRTAC1 variant 2) is a protein that is expressed in the central nervous system (CNS) and is involved in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain.

Recent studies have identified CRTAC1 as a potential drug target (or biomarker) for several neurodegenerative diseases, due to its known role in the development and progression of these conditions.

One of the main reasons for the interest in CRTAC1 as a drug target is its role in the development of neurodegenerative diseases. Studies have shown that CRTAC1 is overexpressed in the brains of individuals with Alzheimer's disease, and that this overexpression is associated with the development of neurodegeneration. Additionally, CRTAC1 has been shown to be overexpressed in the brains of individuals with Parkinson's disease, and this overexpression is also associated with the development of neurodegeneration.

Another reason for the interest in CRTAC1 as a drug target is its role in chronic pain. Studies have shown that CRTAC1 is involved in the development and progression of chronic pain, and that this involvement may be related to its role in neurodegenerative diseases.

In addition to its role in the development and progression of neurodegenerative diseases, CRTAC1 has also been shown to be involved in several other processes in the brain, including the regulation of pain and the development of memories.

Given its involvement in several important processes in the brain, CRTAC1 has potential as a drug target for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and chronic pain.

The identification of CRTAC1 as a potential drug target (or biomarker) has led to further research into its role in these conditions, and has led to the development of new treatments for these diseases.

In conclusion, CRTAC1 (CRTAC1 variant 2) is a protein that is expressed in the central nervous system and is involved in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. As a result, CRTAC1 has potential as a drug target (or biomarker) for these conditions, and has led to further research into its role in these diseases. Further research is needed to fully understand the role of CRTAC1 in these conditions and to develop new treatments for these diseases.

Protein Name: Cartilage Acidic Protein 1

The "CRTAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRTAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets